Related Experiment Video

Updated: May 16, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications

Keizo Sugaya1

  • 1Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, 183-0042, Fuchu, Tokyo, Japan, keizo_sugaya@member.metro.tokyo.jp.

Sub-Cellular Biochemistry
|December 11, 2012
PubMed

Insights

Huntington's disease (HD) and other polyglutamine (polyQ) disorders involve CAG repeat expansions. New models explore how polyQ protein aggregation pathways influence disease progression and predict neurodegeneration timelines.

Area of Science:

  • Neuroscience
  • Genetics
  • Biophysics

Background:

  • Huntington's disease (HD) is a polyglutamine (polyQ) disorder caused by CAG-trinucleotide repeat expansions.
  • Previously, a unifying pathogenic mechanism for polyQ disorders was assumed, but recent findings reveal diverse polyQ protein aggregate structures and toxicities.
  • Disease-specific aspects, like repeat-length dependence, influence clinical features and aggregation propensity.

Purpose of the Study:

  • To explore genotype-phenotype correlations in polyQ diseases using risk-based stochastic kinetic models.
  • To investigate the quantitative link between polyQ aggregation kinetics and clinical data in HD patients.
  • To present a mathematical model for predicting the time course of neurodegeneration in HD.

Main Methods:

  • Description of two risk-based stochastic kinetic models: cumulative-damage and one-hit models.
  • Utilizing repeat-length as an index to model aggregation kinetics and clinical data in HD.
  • Re-evaluation of CAG repeat-length correlations with age-of-onset and disease progression rates.

Main Results:

  • Models reflect alternative pathways of polyQ aggregation.
  • Quantitative connections established between aggregation kinetics and clinical data in HD.
  • A mathematical model is presented for precise prediction of HD neurodegeneration time course.

Conclusions:

  • Kinetic models offer insights into polyQ disorder pathogenesis.
  • Understanding aggregation pathways is crucial for explaining disease mechanisms.
  • Mathematical modeling can precisely predict neurodegeneration in HD, aiding in understanding pathogenesis controversies.

More Related Videos

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...